Hikma launches generic Xeloda in the USA

20 July 2016

Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK) has launched capecitabine tablets 150mg and 500mg, the generic equivalents to Xeloda, through its affiliate West-Ward Pharmaceuticals.

West-Ward’s capecitabine tablets are indicated for adjuvant treatment in patients with Dukes’ C colon cancer, as monotherapy in metastatic colorectal cancer, and in combination with docetaxel or as monotherapy in patients with metastatic breast cancer

According to IMS Health data quoted by Hikma, US sales of capecitabine tablets 150mg and 500mg were around $493 million for the 12 months ending May 2016. Xeloda is marketed by Swiss pharma giant Roche, which reported global sales in 2015 of 519 million Swiss francs ($530 million), despite the drug now being off patent in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK